Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul 29;94(3):313-319.
doi: 10.1590/abd1806-4841.20197938.

Treatment of actinic keratoses and cancerization field of the face and scalp with 0.015% ingenol mebutate gel in Brazilian individuals: safety, tolerability and patients' perspectives

Luiz Gameiro  1 , Luis Fernando Requejo Tovo  2 , José Antonio Sanches Júnior  3 , Ivan Aprahamian  1
Affiliations

Treatment of actinic keratoses and cancerization field of the face and scalp with 0.015% ingenol mebutate gel in Brazilian individuals: safety, tolerability and patients' perspectives

Luiz Gameiro et al. An Bras Dermatol. .

Abstract

Background: Actinic keratosis (AK) represents a risk of progression to squamous cell carcinoma. Ingenol mebutate gel is a novel therapeutic option for field-directed treatment.

Objectives: To evaluate the safety, tolerability and patients' perspectives, related to the therapeutic success of managing AKs on the face and scalp with ingenol mebutate gel in Brazilian individuals.

Methods: This was an observational, retrospective and descriptive study of 68 areas of actinic keratosis on the face and scalp treated with Ingenol mebutate gel involving a total of 37 patients. The drug was applied for three consecutive days on an area of of 25 cm2 and documentation was performed on baseline and days 4, 8, 15, 60 and 180. On day 4, the composite local skin reaction score was calculated. At the end, a questionnaire was applied to evaluate patients' perspectives about the treatment.

Results: Adherence was 100%, no serious adverse events were recorded and the mean composite local skin reaction score (standard deviation) was 8.61±4.22. The treatment was considered optimum by 75.68% of the patients.

Study limitations: Calculation of composite local skin reaction score performed only on the fourth day.

Conclusions: Treatment with ingenol mebutate gel was considered safe and tolerable in Brazilian subjects. Patients had a maximum adherence rate and a great improvement in self-esteem. The results of this research reproduce the findings of the literature.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: Three of the authors received honorarium from LEO Pharma. One as a speaker (Luiz Alberto Gameiro Jr) and the other two as Board consultants (Luís Fernando Requejo Tovo e José Antonio Sanches Jr).

Figures

Graph 1
Graph 1
Local Skin Reaction (LSR) Score
Figure 1
Figure 1
(pre-application/first day of treatment). Day 1
Figure 2
Figure 2
Patient follow-up (severe local skin reaction). Day 4
Figure 3
Figure 3
Patient follow-up (severe local skin reaction). Day 8
Figure 4
Figure 4
Patient follow-up (severe local skin reaction). Day 15
Graph 2
Graph 2
Patients’ perspectives. Answers obtained by the questionnaire at the end of treatment.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Einspahr JG, Stratton SP, Bowden GT, Alberts DS. Chemoprevention of human skin cancer. Crit Rev Oncol Hematol. 2002;41:269–285. - PubMed
    1. Vatve M, Ortonne JP, Birch-Machin MA, Gupta G. Management of field change in actinic keratosis. Br J Dermatol. 2007;157(Suppl 2):21–24. - PubMed
    1. Schmitt JV, Miot HA. Queratoses actínicas: revisão clínica e epidemiológica. An Bras Dermatol. 2012;87:425–434. - PubMed
    1. Landis ET, Davis SA, Taheri A, Feldman SR. Top dermatologic diagnoses by age. Dermatol Online J. 2014;20:22368. - PubMed
    1. Sociedade Brasileira de Dermatologia Nosologic profile of dermatologic visits in Brazil. An Bras Dermatol. 2006;81:549–558.

LinkOut - more resources